Avelas’ AVB-620 (pegloprastide) Receives the US FDA’s Breakthrough Therapy Designation for Use During Breast Cancer Surgery

 Avelas’ AVB-620 (pegloprastide) Receives the US FDA’s Breakthrough Therapy Designation for Use During Breast Cancer Surgery

Avelas’ AVB-620 (pegloprastide) Receives the US FDA’s Breakthrough Therapy Designation for Use During Breast Cancer Surgery

Shots:

  • The US FDA has granted BTD to pegloprastide (AVB-620) for the intraoperative detection and visualization of positive margins during breast cancer surgery
  • Earlier, the company reported results of P-II/III study that demonstrated the use of pegloprastide during surgery correctly identified cancer in ~ 75% of patients who would have otherwise been candidates for a repeat (re-excision) surgery
  • Pegloprastide is designed to deliver a fluorescent marker to cancer cells to aid surgeons in identifying positive margins in real-time during surgery

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: BioSpace

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post